Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Cancer Lett ; 236(1): 54-7, 2006 May 08.
Artículo en Inglés | MEDLINE | ID: mdl-15985325

RESUMEN

Malignant transformation of ovarian cells of surface epithelial origin is associated with expression of a membrane-spanning glycoprotein, cancer antigen (CA)-125. The bulk of the putative CA-125 molecule is comprised a very large, folded, multivalent, mucin-like exodomain. That the extracellular motif of CA-125 exerts immunosuppressive effects which promote tumor progression has been suggested. We report that CA-125 attenuates complement lysis of antibody-sensitized cells. The secreted form of CA-125 derived from culture medium of the human ovarian adenocarcinoma cell line OVCAR-3 caused a dose-response inhibition of sheep erythrocyte hemolysis. Moreover, OVCAR-3 cells became prone to complement attack (trypan blue uptake) mediated by a gonadotropin-releasing hormone receptor antibody when (membrane-bound) CA-125 was excised/removed by trypsin/washing; this effect was counteracted by replacement with (soluble) CA-125. It is conceivable that CA-125 entraps/sheds effectors of the complement cascade.


Asunto(s)
Antígeno Ca-125/farmacología , Línea Celular Tumoral/inmunología , Activación de Complemento/efectos de los fármacos , Inactivadores del Complemento/farmacología , Animales , Anticuerpos/inmunología , Anticuerpos/farmacología , Antígeno Ca-125/aislamiento & purificación , Ensayo de Actividad Hemolítica de Complemento , Citotoxicidad Inmunológica/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Eritrocitos/efectos de los fármacos , Eritrocitos/inmunología , Femenino , Hemólisis , Humanos , Neoplasias Ováricas , Receptores LHRH/inmunología , Ovinos , Factores de Tiempo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA